四价牛-人重配轮状病毒减毒活疫苗(BRV-TV)在印度婴儿中的随机对照III期研究
该III期单盲随机对照研究纳入1182名健康婴儿,按1:1随机接受三剂BRV-TV或RV5,并与DTwP-HepB-Hib和OPV同时接种。BRV-TV组轮状病毒血清IgA血清应答率47.1% vs RV5组61.2%,组间差-14.08%(95%CI:-20.4;-7.98),未达到免疫原性非劣效标准。两组对常规疫苗的血清保护/血清应答均达标,安全性相似。
要点
- BRV-TV组轮状病毒血清IgA血清应答率47.1% vs RV5组61.2%,未达非劣效标准。
- BRV-TV组血清IgA几何平均浓度28.4 U/ml vs RV5组50.1 U/ml(第3剂后28天)。
- 两组对DTwP-HepB-Hib和OPV所有抗原的血清保护/血清应答均满足-10%非劣效标准。
核心结论
- BRV-TV具有免疫原性,但与常规儿童抗原同时接种时未达到对RV5的免疫原性非劣效标准。
研究设计与样本
- III期单盲(家长设盲)随机对照研究,在健康婴儿中按1:1随机接受三剂BRV-TV或RV5,接种年龄为6-8、10-12和14-16周。
- 筛查1195名婴儿,随机化1182名(BRV-TV组590名,RV5组592名)。
- 所有婴儿同时接种DTwP-HepB-Hib联合疫苗和OPV。
主要发现
- 轮状病毒血清IgA血清应答率:BRV-TV组47.1%(95%CI:42.8;51.5)vs RV5组61.2%(95%CI:56.8;65.5),组间差-14.08%(95%CI:-20.4;-7.98)。
- 第3剂后28天血清IgA几何平均浓度:BRV-TV组28.4 U/ml vs RV5组50.1 U/ml。
- 对DTwP-HepB-Hib和OPV所有抗原,两组均产生血清保护/血清应答,且满足组间-10%非劣效标准。
- 严重不良事件共16例,BRV-TV组10例 vs RV5组6例,均未归类为疫苗相关;两组疫苗安全性特征相似。
关键数值与推荐
- 血清应答定义为从基线至第3剂后第28天滴度≥4倍升高。
- 非劣效标准为组间差异的95%CI下限高于-10%。
- 轮状病毒血清IgA血清应答非劣效性未成立:BRV-TV组47.1% vs RV5组61.2%,组间差-14.08%(95%CI:-20.4;-7.98)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rotavirus remains the leading cause of diarrhoea among children <5years. We assessed immunogenic non-inferiority of a tetravalent bovine-human reassortant rotavirus vaccine (BRV-TV) over the licensed human-bovine pentavalent rotavirus vaccine RV5. METHODS: Phase III single-blind study (parents blinded) in healthy infants randomized (1:1) to receive three doses of BRV-TV or RV5 at 6-8, 10-12, and 14-16weeks of age. All concomitantly received a licensed diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b conjugate vaccine (DTwP-HepB-Hib) and oral polio vaccine (OPV). Immunogenic non-inferiority was evaluated in terms of the inter-group difference in anti-rotavirus serum IgA seroresponse (primary endpoint), and seroprotection/seroresponse rates to DTwP-HepB-Hib and OPV vaccines. Seroresponse was defined as a ≥4-fold increase in titers from baseline to D28 post-dose 3. Non-inferiority was declared if the difference between groups (based on the lower limit of the 95% confidence interval [CI]) was above -10%. Each subject was evaluated for solicited adverse events 7days and unsolicited & serious adverse events 28days following each dose of vaccination. RESULTS: Of 1195 infants screened, 1182 were randomized (590 to BRV-TV; 592 to RV5). Non-inferiority for rotavirus serum IgA seroresponse was not established: BRV-TV, 47.1% (95%CI: 42.8; 51.5) versus RV5, 61.2% (95%CI: 56.8; 65.5); difference between groups, -14.08% (95%CI: -20.4; -7.98). Serum IgA geometric mean concentrations at D28 post-dose 3 were 28.4 and 50.1U/ml in BRV-TV and RV5 groups, respectively. For all DTwP-HepB-Hib and OPV antigens, seroprotection/seroresponse was elicited in both groups and the -10% non-inferiority criterion between groups was met. There were 16 serious adverse events, 10 in BRV-TV group and 6 in RV5 group; none were classified as vaccine related. Both groups had similar vaccine safety profiles. CONCLUSION: BRV-TV was immunogenic but did not meet immunogenic non-inferiority criteria to RV5 when administered concomitantly with routine pediatric antigens in infants.
引用
- Saluja T, Palkar S, Misra P, et al. Live attenuated tetravalent (G1-G4) bovine-human reassortant rotavirus vaccine (BRV-TV): Randomized, controlled phase III study in Indian infants. Vaccine. 2017. PMID: 28536027. doi:10.1016/j.vaccine.2017.05.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。